Design and synthesis of pinanamine derivatives as anti-influenza A M2 ion channel inhibitors

[Display omitted] ► A series of pinanamine derivatives were design and synthesized for M2 inhibitors. ► Several imidazole and guanazole substituted compounds were found to inhibit WT A/M2 as potent as amantadine. ► Compound 12 was identified to be a novel inhibitor against both A/M2-WT and A/M2-S31N...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antiviral research 2012-11, Vol.96 (2), p.91-99
Hauptverfasser: Zhao, Xin, Jie, Yanling, Rosenberg, Matthew R., Wan, Junting, Zeng, Shaogao, Cui, Wei, Xiao, Yiping, Li, Zhiyuan, Tu, Zhengchao, Casarotto, Marco G., Hu, Wenhui
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] ► A series of pinanamine derivatives were design and synthesized for M2 inhibitors. ► Several imidazole and guanazole substituted compounds were found to inhibit WT A/M2 as potent as amantadine. ► Compound 12 was identified to be a novel inhibitor against both A/M2-WT and A/M2-S31N mutant channels. The adamantanes are a class of anti-influenza drugs that inhibit the M2 ion channel of the influenza A virus. However recently, the clinical effectiveness of these drugs has been called into question due to the emergence of adamantane-insensitive A/M2 mutants. Although we previously reported (1R,2R,3R,5S)-3-pinanamine 3 as a novel inhibitor of the wild type influenza A virus M2 protein (WT A/M2), limited inhibition was found for adamantane-resistant M2 mutants. In this study, we explored whether newly synthesized pinanamine derivatives were capable of inhibiting WT A/M2 and selected adamantane-resistant M2 mutants. Several imidazole and guanazole derivatives of pinanamine were found to inhibit WT A/M2 to a comparable degree as amantadine and one of these compounds 12 exhibits weak inhibition of A/M2-S31N mutant and it is marginally more effective in inhibiting S31NM2 than amantadine. This study provides a new insight into the structural nature of drugs required to inhibit WT A/M2 and its mutants.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2012.09.001